Hbm Holdings Ltd (2142.HK) stock: key figures, P/E, revenue and dividend
Health Care · Hong Kong · ISIN KYG4403H1002
Hbm Holdings Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 38.00 m USD | 157.98 m USD |
| Gross profit | 33.00 m USD | 149.24 m USD |
| Operating income | – | 82.38 m USD |
| EBIT | -2.00 m USD | – |
| Net income | 2.78 m USD | 91.33 m USD |
| Diluted EPS – continuing operations | 0.00 USD | 0.11 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Hbm Holdings Ltd
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm. It is developing HBM7020 for treating hepatocellular carcinoma and autoimmune diseases; HBM9378 for the treatment of asthma and chronic obstructive pulmonary disease; and HBM1020, HBM7022, HBM7008, HBM9027, HBM7004, and HBM9033 for treating solid tumors. The company has a strategic collaboration with Evinova to apply AI and digital technologies to enhance the efficiency of biologics development. The company was incorporated in 2016 and is based in Suzhou, the People's Republic of China.
More stocks
- ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD. (301234.SZ)
- COMPASS Pathways plc (CMPS)
- RLH Properties S.A.B. de C.V (RLHA.MX)
- ShenZhen Kondarl Group Co Ltd (000048.SZ)
- Shanghai Ziyan Foods Co Ltd (603057.SS)
- Accel Entertainment, Inc. (ACEL)
- Pacific Horizon Investment Trust PLC (PHI.L)
- Oaktree Specialty Lending Corp (OCSL)
- Growthpoint Properties Australia Ltd (GOZ.AX)
- Nagarro (NA9.DE)
- Sinar Mas Agro Resources and Technology Tbk PT (SMAR.JK)
- IRADIMED CORP (IRMD)
Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.